82 related articles for article (PubMed ID: 28691425)
1. Tolerance of combined radiochemotherapy in cervical cancer patients.
Izmajłowicz B; Rusiecka M; Sztuder A; Stępień M; Ignatowicz-Pacyna A; Słocka-Romaniuk B; Mazur Z; Kornafel J
Adv Clin Exp Med; 2017 Jul; 26(4):587-594. PubMed ID: 28691425
[TBL] [Abstract][Full Text] [Related]
2. Role of Surgical Versus Clinical Staging in Chemoradiated FIGO Stage IIB-IVA Cervical Cancer Patients-Acute Toxicity and Treatment Quality of the Uterus-11 Multicenter Phase III Intergroup Trial of the German Radiation Oncology Group and the Gynecologic Cancer Group.
Marnitz S; Martus P; Köhler C; Stromberger C; Asse E; Mallmann P; Schmidberger H; Affonso Júnior RJ; Nunes JS; Sehouli J; Budach V
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):243-53. PubMed ID: 26853333
[TBL] [Abstract][Full Text] [Related]
3. Clinical value of concurrent radiochemotherapy in cervical cancer and comparison of ultrasonography findings before and after radiochemotherapy.
Yan WM; Li XZ; Yu ZL; Zhang J; Sun XG
Genet Mol Res; 2015 Apr; 14(2):3633-9. PubMed ID: 25966132
[TBL] [Abstract][Full Text] [Related]
4. [Estimation of treatment results and side-effects in patients with invasive uterine cervix cancer stage IIB-IVA treated with concurrent radiochemotherapy].
Torbé B
Ann Acad Med Stetin; 2008; 54(1):28-40. PubMed ID: 19127807
[TBL] [Abstract][Full Text] [Related]
5. Role of serum VEGFA, TIMP2, MMP2 and MMP9 in monitoring response to adjuvant radiochemotherapy in patients with primary cervical cancer--results of a companion protocol of the randomized NOGGO-AGO phase III clinical trial.
Braicu EI; Gasimli K; Richter R; Nassir M; Kümmel S; Blohmer JU; Yalcinkaya I; Chekerov R; Ignat I; Ionescu A; Mentze M; Fotopoulou C; Pop C; Lichtenegger W; Sehouli J; ;
Anticancer Res; 2014 Jan; 34(1):385-91. PubMed ID: 24403492
[TBL] [Abstract][Full Text] [Related]
6. Clinical features, outcome and risk factors in cervical cancer patients after surgery for chronic radiation enteropathy.
Yang J; Ding C; Zhang T; Zhang L; Lv T; Ge X; Gong J; Zhu W; Li N; Li J
Radiat Oncol; 2015 Jun; 10():128. PubMed ID: 26047616
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of bevacizumab in combination with definitive radiotherapy and cisplatin chemotherapy in untreated patients with locally advanced cervical carcinoma: preliminary results of RTOG 0417.
Schefter TE; Winter K; Kwon JS; Stuhr K; Balaraj K; Yaremko BP; Small W; Gaffney DK
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1179-84. PubMed ID: 22342094
[TBL] [Abstract][Full Text] [Related]
8. Radiochemotherapy combined with regional pelvic hyperthermia induces high response and resectability rates in patients with nonresectable cervical cancer > or =FIGO IIB "bulky".
Sreenivasa G; Hildebrandt B; Kümmel S; Jungnickel K; Cho CH; Tilly W; Böhmer D; Budach V; Felix R; Wust P
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1159-67. PubMed ID: 16979843
[TBL] [Abstract][Full Text] [Related]
9. HDR brachytherapy combined with interstitial hyperthermia in locally advanced cervical cancer patients initially treated with concomitant radiochemotherapy--a phase III study.
Zolciak-Siwinska A; Piotrkowicz N; Jonska-Gmyrek J; Nicke-Psikuta M; Michalski W; Kawczyńska M; Bijok M; Bujko K
Radiother Oncol; 2013 Nov; 109(2):194-9. PubMed ID: 23684588
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study.
Naik A; Gurjar OP; Gupta KL; Singh K; Nag P; Bhandari V
Cancer Radiother; 2016 Jul; 20(5):370-6. PubMed ID: 27368915
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of planning aims and dose prescription in image-guided adaptive brachytherapy and radiochemotherapy for cervical cancer: Vienna clinical experience in 225 patients from 1998 to 2008.
Majercakova K; Pötter R; Kirisits C; Banerjee S; Sturdza AE; Georg P; Nesvacil N; Schmid MP
Acta Oncol; 2015; 54(9):1551-7. PubMed ID: 26198658
[TBL] [Abstract][Full Text] [Related]
12. [Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR].
Haie-Meder C; Fervers B; Chauvergne J; Fondrinier E; Lhommé C; Guastalla JP; Resbeut M
Bull Cancer; 1999 Oct; 86(10):829-41. PubMed ID: 10572234
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: A phase II trial.
Wang X; Shen Y; Zhao Y; Li Z; Gou H; Cao D; Yang Y; Qiu M; Li Q; Liu J; Yi C; Liao Z; Luo D; Xu F; Bi F
Eur J Surg Oncol; 2015 Aug; 41(8):1082-8. PubMed ID: 26033265
[TBL] [Abstract][Full Text] [Related]
14. Normal tissue complication probability analysis of acute gastrointestinal toxicity in cervical cancer patients undergoing intensity modulated radiation therapy and concurrent cisplatin.
Simpson DR; Song WY; Moiseenko V; Rose BS; Yashar CM; Mundt AJ; Mell LK
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e81-6. PubMed ID: 22516388
[TBL] [Abstract][Full Text] [Related]
15. Dose escalated intensity modulated radiotherapy in the treatment of cervical cancer.
Cihoric N; Tsikkinis A; Tapia C; Aebersold DM; Zlobec I; Lössl K
Radiat Oncol; 2015 Nov; 10():240. PubMed ID: 26597282
[TBL] [Abstract][Full Text] [Related]
16. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study.
Gandhi AK; Sharma DN; Rath GK; Julka PK; Subramani V; Sharma S; Manigandan D; Laviraj MA; Kumar S; Thulkar S
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):542-8. PubMed ID: 24074927
[TBL] [Abstract][Full Text] [Related]
17. Nadroparine activated fibrinolysis and improvement of glomerular filtration rate in patients with FIGO IIB-IIIB cervical cancer treated with radiochemotherapy.
Derlatka P; Bidzinski M; Stachurska E; Benke M
Gynecol Oncol; 2007 Jan; 104(1):24-31. PubMed ID: 16959304
[TBL] [Abstract][Full Text] [Related]
18. The Efficacy of Palonosetron Plus Dexamethasone in Preventing Chemoradiotherapy-induced Nausea and Emesis in Patients Receiving Daily Low-dose Cisplatin-based Concurrent Chemoradiotherapy for Uterine Cervical Cancer: A Phase II Study.
Mitsuhashi A; Usui H; Nishikimi K; Yamamoto N; Hanawa S; Tate S; Watanabe-Nemoto M; Uno T; Shozu M
Am J Clin Oncol; 2017 Apr; 40(2):118-121. PubMed ID: 25144265
[TBL] [Abstract][Full Text] [Related]
19. Frequency and Severity of Acute Toxicity of Pelvic Radiotherapy for Gynecological Cancer.
Hafiz A; Abbasi AN; Ali N; Khan KA; Qureshi BM
J Coll Physicians Surg Pak; 2015 Nov; 25(11):802-6. PubMed ID: 26577965
[TBL] [Abstract][Full Text] [Related]
20. Acute small-bowel toxicity during neoadjuvant combined radiochemotherapy in locally advanced rectal cancer: determination of optimal dose-volume cut-off value predicting grade 2-3 diarrhoea.
Reis T; Khazzaka E; Welzel G; Wenz F; Hofheinz RD; Mai S
Radiat Oncol; 2015 Jan; 10():30. PubMed ID: 25636703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
